Issue 14, 2023
From the journal:

Journal of Materials Chemistry B

Iron nitroprusside as a chemodynamic agent and inducer of ferroptosis for ovarian cancer therapy†

Kanwal Asif, ORCID logo ab   Muhammad Adeel,*ab   Md. Mahbubur Rahman, ORCID logo *c   Isabella Caligiuri,b   Tiziana Perin,b   Maja Cemazar,d   Vincenzo Canzonieri ORCID logo be  and  Flavio Rizzolio ORCID logo *ab  

* Corresponding authors

a Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, Venice, Italy
E-mail: muhammad.adeel@unive.it, flavio.rizzolio@unive.it

b Pathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS, Aviano, Italy

c Department of Applied Chemistry, Konkuk University, Chungju 27478, Republic of Korea
E-mail: mahbub1982@kku.ac.kr

d Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, Slovenia

e Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy

Abstract

ChemoDynamic Therapy (CDT) is a powerful therapeutic modality using Fenton/Fenton-like reactions to produce oxidative stress for cancer treatment. However, the insufficient amount of catalyst ions and ROS scavenging activity of glutathione peroxidase (GPX4) limit the application of this approach. Therefore, a tailored strategy to regulate the Fenton reaction more efficiently (utilizing dual metal cations) and inhibit the GPX4 activity, is in great demand. Herein, a CDT system is based on dual (Fe2+ metals) iron pentacyanonitrosylferrate or iron nitroprusside (FeNP) having efficient ability to catalyze the reaction of endogenous H2O2 to form highly toxic ˙OH species in cells. Additionally, FeNP is involved in ferroptosis via GPX4 inhibition. In particular, FeNP was structurally characterized, and it is noted that a minimum dose of FeNP is required to kill cancer cells while a comparable dose shows negligible toxicity on normal cells. Detailed in vitro studies confirmed that FeNP participates in sustaining apoptosis, as determined using the annexin V marker. Cellular uptake results showed that in a short time period, FeNP enters lysosomes and, due to the acidic lysosomal pH, releases Fe2+ ions, which are involved in ROS generation (˙OH species). Western blot analyses confirmed the suppression of GPX4 activity over time. Importantly, FeNP has a therapeutic effect on ovarian cancer organoids derived from High-Grade Serous Ovarian Cancer (HGSOC). Furthermore, FeNP showed biocompatible nature towards normal mouse liver organoids and in vivo. This work presents the effective therapeutic application of FeNP as an efficient Fenton agent along with ferroptosis inducer activity to improve CDT, through disturbing redox homeostasis.

Graphical abstract: Iron nitroprusside as a chemodynamic agent and inducer of ferroptosis for ovarian cancer therapy

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/D2TB02691K
Article type
Paper
Submitted
10 Dec 2022
Accepted
09 Feb 2023
First published
08 Mar 2023
This article is Open Access
Creative Commons BY-NC license

J. Mater. Chem. B, 2023,11, 3124-3135

Permissions

Request permissions

Iron nitroprusside as a chemodynamic agent and inducer of ferroptosis for ovarian cancer therapy

K. Asif, M. Adeel, Md. M. Rahman, I. Caligiuri, T. Perin, M. Cemazar, V. Canzonieri and F. Rizzolio, J. Mater. Chem. B, 2023, 11, 3124 DOI: 10.1039/D2TB02691K

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements